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Abstract  
Background: Heart disease is one of the leading causes of death in Indonesia. Nutritional 
management plays an important role in overcoming heart disease, both as prevention and 
treatment. Carnitine plays a role in fat metabolism and can reduce the formation of thrombosis, 
resulting in improved heart function and quality of life of patients. 
Objectives: This study is aimed to identify the effect of carnitine in patients with heart failure. 
Methods: Existing research findings and articles are selected based on inclusion and exclusion 
criteria in three databases, namely PubMed, Cochrane and Wiley. The outcome were functional 
capacity and heart function. 
Results: One meta-analysis that address with the clinical questions was obtained, and based on that 
article, giving carnitine to patients with heart failure has effects on increasing functional capacity, 
heart function, BNP serum and NT-proBNP levels. However, no effects found on mortality. 
Furthermore, no significant side effects on carnitine was found. 
Conclusions: Carnitine supplementation at a dose of 1 up to 6 g/day has a positive impact on 
functional capacity, heart function, BNP serum and NT-proBNP levels in patients with heart failure, 
alongside with minimal side effects. 
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Clinical scenario 
 
Mr. S, age 50, was admitted to the emergency room 
with the chief complaint of shortness of breath for 
the last 3 days, which would arise suddenly and 
became worse when in a sleeping position. History 
of diabetes was denied, however he had a history of 
high blood pressure for the past one year and was not 
taking medications regularly. Physical examination  
 
 
revealed cardiomegaly, normal heart sounds, no 
murmurs or gallops.  Laboratory results: Hb 16 
g/dL, leukocytes 6500/mm3, platelets 230,000/uL, 
LDL 243 mg/dL, triglycerides 267 mg/dL, uric acid 
10 mg/dL, troponin I 0.29 ng/mL, BNP 312 pg/mL. 
Electrocardiography test showed an enlarged left 
ventricle. The patient's body weight was 65.7 kg, 
with a height of 160 cm, and a body mass index of 
25.6 kg/m2. The patient was hospitalized and 
received treatment from internists and clinical 
nutrition specialists. Patient was diagnosed with 
obesity grade 1,1 heart failure class 4 according to 
the New York Heart Association (NYHA), 
dyslipidemia, and hyperuricemia. Patient was given 
oral carnitine supplementation when discharged 
from the hospital at a dose of 1.5 g/day for 3 months 
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period, and showed an improvement in NYHA class. 
Patient did not show any side effects after carnitine 
supplementation. 
 
Introduction 
 
Heart failure is a global problem with 26 million 
people worldwide and with 670,000 new cases 
found in America. Heart failure is the most common 
cause for hospital admittance in the United States 
and Europe.2 In Indonesia, heart failure prevalence 
is 5%, with mortality rate up to 20%.3 
One of the nutrients that has been found having 
an essential role for patients with heart failure is 
carnitine, which is an amino acid derivative that 
plays a role in fat metabolism and mitochondrial 
defence. Several studies have shown that carnitine, 
especially in the form of propionyl-L-carnitine, can 
reduce the accumulation of coronary artery 
thrombosis and embolism. Some sources of 
carnitine are milk and milk products, and red meat. 
The role of carnitine in fat metabolism is as the 
transporter of acyl co-A into the mitochondrial 
matrix, so that fat can undergo β-oxidation and 
become a source of energy, especially for heart 
muscle cells.4 Healthy adult usually consume 
carnitine at a dose of 2-5 mg/kgBW/day.5  
Patients with heart failure often suffer from 
carnitine insufficiency due to reduced intake, 
malabsorption, and decreased muscle mass. 
Carnitine insufficiency results in reduced left 
ventricular diastolic function, reduced physical 
activity ability, and an increased risk of heart attack.7 
However, carnitine has not yet been recommended 
as a routine therapy in patients with heart failure by 
the American College of Cardiology Foundation / 
American Heart Association (ACCF / AHA).8 Even 
so, giving carnitine can be a nutritional therapy for 
patients with heart failure that can help improve 
heart function and the quality of life of patients. Jing 
et al.9 carried out a research by administering 
carnitine intravenously twice a day for seven days, 
in the form of 1 g of L-carnitine dissolved in 100mL 
of normal saline in patients with heart failure. The 
assessment was carried out on the NYHA class of 
patients. The results showed a 60.9% improvement 
in the NYHA class of intervention group, compared 
to the 44.7% improvement in the NYHA class of 
placebo group. A meta-analysis study of the effects 
of carnitine given orally in accordance with the 
needs of 3 g/day or more on mortality rate in patients 
with acute myocardial infarction did not show any 
significant impact.10  
This evidence-based case report will discuss 
specifically about the effects of carnitine on patients 
with heart failure. 
 
Clinical questions 
P: Adult patients with heart failure 
I: Carnitine 
C: Without carnitine 
O: Functional capacity and heart function  
Clinical question: What is the effect of carnitine as a 
nutritional management on functional capacity and 
heart function in patients with heart failure? 
 
Methods 
 
Article Search Strategy 
Existing research articles were generated from 
PubMed, Cochrane Library, and Wiley Online on 
December 12, 2019. Searching terminology is 
described in Table 1. 
 
Article Selection Strategy 
 
Eligibility Criteria 
Screening is based on MesH Term, an assessment of 
conformity with PICO, and with inclusion and 
exclusion criteria. The inclusion criteria were 1. 
Study subjects were adult patients (aged ≥18 years 
old), 2. Subjects diagnosed with heart failure with 
various stages 3. Clinical trials or meta-analysis with 
carnitine treatment 4. Journals published in the last 
5 years 5. Tests clinically carried out in humans. 
Meanwhile, the exclusion criteria were 1. Journal is 
not written in English and 2. full text is not available. 
 
Method of critical appraisal 
All authors did the critical appraisal by using the 
method according to the Center of Evidence Based 
Medicine (www.cebm.net) for intervention studies 
that has been modified in Indonesian language. 
 
Findings 
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Based on the results of the search from the database, 
and by assessing the inclusion and exclusion criteria, 
an article that is eligible to be included as a reference 
for critical review is used (Figure 1). 
Selected articles are meta-analysis of clinical trials, 
with a total number of 1625 patients. The length of 
follow-up of the subject in the articles is from 7 days 
to 3 years. Carnitine given to patients with a dose of 
1 to 6 g/day. 
The articles obtained have a level of evidence 1, 
which is a meta-analysis of 17 clinical trials. 
Findings from articles used in this work illustrate 
that carnitine administration has a positive impact on 
functional capacity and heart function. The validity 
of the criteria can be seen in table 3. The relevance 
of the criteria can be seen in table 4. 
There were no differences of mortality rate in 
patients with heart failure (p= 0.08) and carnitine 
side effects (p=0.83), there was an increase in 
functional capacity marked by a decrease in NYHA 
class (p<0.01), decrease in BNP serum markers 
(p=0.01) and NT-proBNP (p<0.01), as well as 
increased cardiac function (p<0.01). 
 
Discussion 
 
Song X et al. conducted a meta-analysis study for 
the effects of carnitine supplementation on patients 
with heart failure with a search time limit until 
September 30, 2016. The study looked for 
randomized controlled literature from various 
databases, abstracts of scientific meetings, as well as 
manually from unpublished articles and studies. 
Based on the search, 17 appropriate journals were 
found, with a total of 1625 research subjects. 
Patients’ age ranged between 43 and 78 years. 
Carnitine dosage given ranged from 1 to 6 g/day, and 
administered from 7 days to 3 years. Patients 
receiving carnitine were clasified as NYHA class II-
IV, with a LVEF of 27% to 52% before the 
intervention. 
Outcomes from this study showed that carnitine 
had a positive impact on the functional capacity, 
which is characterized by a decrease in NYHA 
class.11 The literature that has the greatest weight in 
the meta-analysis was the research conducted by 
Jing ZC et al. The study gave carnitine of 1 g 
intravenously, twice a day for seven days. The 
effectiveness of carnitine reached 60.7% compared 
to the control group of 44.7% (P = 0.012). The 6-
minute walk test did not show significant difference 
between control and intervention (P = 0.14).9 The 
study from Song X et al. also showed that carnitine 
had positive effect on serum-BNP (P = 0.01) and 
NT-proBNP (P = 0.0003). Both BNP and NT-
proBNP can act as prognostic factors in patients with 
heart failure or in patients with asymptomatic left 
ventricular dysfunction.11  
The heart function also showed significant 
improvement. The heart functions assessed were 
LVEF (P <0.00001), SV (P <0.00001), CO (P 
<0.00001), E / A ratio (P = 0.0003), LVESD (P = 
0.002) ), LVEDD (P <0.0001), and LVESV (P = 
0.01).11 The antioxidant effect of carnitine can 
prevent the formation of superoxide in heart muscle 
and excessive inflammation, which results in 
changes in heart structure.4 
There was no impact on the mortality of patients 
with heart failure, both in intention to treat analysis 
and per protocol. From a total of ten literature, six 
literatures showed no side effects of carnitine 
administration in patients with heart failure, while 
four studies report side effects such as dry mouth 
and gastrointestinal disorders. One literature 
reported that there was skin rash as a side effect, but 
it did occur in both treatments, both the control 
group and the intervention group.11 
Based on the article in this evidence-based case 
report, it can be concluded that administration of 
carnitine can improve the quality of life of patients 
with heart failure, improve heart function and serum 
levels of BNP and NT-proBNP, with minimal side 
effects. Carnitine can be given orally by using 
carnitine supplements, and using food sources. 
Examples of food sources of carnitine are beef, with 
carnitine of 2320 mg/kg dry weight, duck meat with 
carnitine 732 mg/kg dry weight, skim milk with 
carnitine 400 mg/kg dry weight, condensed milk 396 
mg/kg dry weight, and yogurt 142-139 mg/kg dry 
weight. 
 
Recommendation: 
Patients with heart failure can be given carnitine at 
least 1 g/day to 6 g/day. In administration of 
carnitine at a dose of 1 g, it can be given for 1 year, 
a dose of 1.5 g carnitine with a duration of 3 months, 
while a dose of 3 g and 6 g can be given for 7 days 
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Conclusion 
 
Patients included in defined clinical scenario can be 
given carnitine up to 6 g/day, in the form of 
supplementation or derived from food sources such 
as milk, milk products, or meat. Giving carnitine can 
improve the quality of life of patients, heart function, 
reduce BNP serum and NT-proBNP levels, with 
minimal side effects. Giving carnitine has no impact 
on the mortality of patients with heart failure. 
 
 
 
  
 
 
Figure 1. PRISMA flow chart 
 
 
PubMed
(n=116)
Cochrane
(n=18)
Records after duplicates removed
(n=125)
Records screened
(n=1)
Excluded:
- More than 5 years
(n=104)
- Animal experiment (n=5)
- No fulltext available (n=1)
- Clinical trial in children 
(n=1)
- Neither clinical trial nor 
meta analysis (n=12)
- No carnitine intervention 
(n=1)
Full-text assessed for eligibility
(n=1)
Inclusion criteria
- Adult
- Heart failure from any stages
- Meta analysis or clinical trial 
with carnitine intervention
- Journal from the last 5 years
- Clinical trial on human
Exclusion criteria
- Not in English
- No fulltext
Search date: 12 Dec 2019
Studies included
(n=1)
“carnitine” AND “heart failure”
Wiley
(n=6)
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Table 1. Terminology 
Database 
 
Terminology Hits Eligible 
PubMed 
 
(((carnitine[MeSH Terms]) OR carnitine[Title])) AND ((heart failure[MeSH 
Terms]) OR heart failure[Title]) 
 
116 1 
Cochrane 
Library 
ID  Search                               Hits 
#1  "heart failure"                                 28578 
#2  carnitine    1705 
 
#3  MeSH descriptor: [Carnitine] explode all trees      606 
#4  MeSH descriptor: [Heart Failure] explode all trees    8482 
#5  #2 OR #3                                1719 
#6  #4 AND #6                              18 
 
18 0 
Wiley 
Online 
Library 
“carnitine” AND “heart failure” in Keywords 6 0 
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Patients with 
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Table 3. Validity criteria 
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Artikel 
Co
m
m
on
 
po
in
t 
Fo
llo
w
 u
p  
Bl
in
d 
fa
sh
io
n  
Su
b-
gr
ou
p 
an
al
ys
is 
O
ut
co
m
e  
Pr
ec
ise
 
A
pp
ly
 
Im
po
rta
nt
 
Song X, et al 
(2017)11 
+ + -* + + + + + A 1 
* Only 3 journals stated that there was blinding in patients and study members 
Tabel 4. Relevance criteria 
Article Similarity Population Similarity determinant/ intervention/ indicators Similarity Outcome 
Song X, et al 
(2017)11 + + + 
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